Related Posts
Additional Posts in Pharma and Biotech
New to Fishbowl?
Download the Fishbowl app to
unlock all discussions on Fishbowl.
unlock all discussions on Fishbowl.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Download the Fishbowl app to unlock all discussions on Fishbowl.
Copy and paste embed code on your site

Scan your QR code to download
Fishbowl app on your mobile

Mentor
• GSK is reportedly in talks to acquire IDRx for around $1 billion, strengthening its oncology pipeline.
• Eli Lilly is eyeing Scorpion Therapeutics in a deal that could reach $2.5 billion, signaling a deeper push into precision oncology.
• Biogen made headlines late Friday with an offer to acquire Sage Therapeutics, aiming to bolster its neuroscience portfolio.
• Johnson & Johnson is exploring a potential acquisition of Intra-Cellular Therapies, a leader in CNS therapeutics.
• Meanwhile, Gilead and LEO Pharma have announced a strategic partnership to accelerate the development of their oral STAT6 program, targeting multiple inflammatory diseases.
Mentor
J&J paid $14.5B for Intra-Cellular Therapies
This was wild